Hypercor 2.5

Bisoprolol fumarate

Monotherapy or in combination w/ other classes of antihypertensives in management of HTN.

HTN Initially 2.5-5 mg once daily. Patients w/ inadequately controlled BP w/ initial dosage Increase dose gradually w/ at least 2-wk interval. Max: 20 mg once daily. Severe hepatic or renal impairment w/ CrCl <40 mL/min Initially 2.5 mg once daily, CrCl <20 mL/min Max: 10 mg daily.

May be taken with or without food.

Patients w/ uncontrolled heart failure or acutely decompensated heart failure requiring IV inotropic therapy; cardiogenic shock; 2nd or 3rd-degree AV block; sinus bradycardia; severe peripheral arterial disease; hypotension; metabolic acidosis; bronchospasm or asthma or those w/ history of obstructive airways disease; phaeochromocytoma w/o α-blockers therapy given.

History of severe anaphylaxis. Avoid in patients w/ Prinzmetal's angina. Not to stop treatment abruptly especially in patients w/ ischaemic heart disease. Precipitate or aggravate symptoms of arterial insufficiency in patients w/ peripheral vascular & Raynaud disease; thyroid storm w/ abrupt w/drawal. Patients w/ diabetes; 1st-degree AV block; hyperthyroidism; psoriasis or w/ history of psoriasis. Monitor for progression of arterial obstruction. Pregnancy & lactation. May increase risk of adverse maternal outcomes w/ untreated chronic HTN. Monitor fetal growth during pregnancy; newborn for 48 hr after delivery for bradycardia, hypoglycemia & resp depression.

Cardiac arrhythmia & failure, chest pain, claudication, cold extremities, edema, flushing, hypersensitivity angiitis, hypotension, orthostatic hypotension, palpitations; anxiety, depression, dizziness, drowsiness, fatigue, headache, hyper- & hypoesthesia, insomnia, lack of conc, malaise, memory impairment, paresthesia, restlessness, eye pressure sensation, twitching, vertigo, vivid dream; acne vulgaris, alopecia, diaphoresis, eczema, pruritus, skin irritation & rash; decreased libido, gout, increased serum glucose, phosphate, K, triglycerides, uric acid, wt gain; abdominal pain, constipation, diarrhea, dysgeusia, dyspepsia, epigastric & gastric pain, gastritis, nausea, peptic ulcer, vomiting, xerostomia; cystitis, impotence; decreased WBC count, +ve ANA titers, purpuric rash, thrombocytopenia; increased serum ALT & AST; back & neck pain, muscle cramps, myalgia, tremor; abnormal lacrimation, eye pain, visual disturbance; otalgia, tinnitus; increased BUN, serum creatinine, polyuria, renal colic; asthma, bronchitis, bronchospasm, cough, dyspnea, dyspnea on exertion, pharyngitis, rhinitis, sinusitis, URTI; angioedema, arthralgia, asthenia, auditory impairment, bradycardia, dermatitis, exfoliative dermatitis, Peyronie disease, psoriasis, sleep disturbance, syncope, unsteadiness.

Increased levels/effects of α₁-blockers, α₂-agonists, amifostine, antipsychotic agents (eg, phenothiazines), 2nd generation antipsychotics (atypical), bradycardia-causing agents, bromperidol, bupivacaine, cardiac glycosides, ceritinib, cholinergic agonists, disopyramide, duloxetine, ergot derivatives, fexinidazole, fingolimod, grass pollen allergen extr (5 grass extr), hypotension-associated agents, insulins, ivabradine, lacosamide, levodopa-containing products, systemic/topical lidocaine, mepivacaine, methacholine, nitroprusside, pholcodine, siponimod, sulfonylureas. Increased levels/effects w/ acetylcholinesterase inhibitors, alfuzosin, α₂-agonists, aminoquinolines (antimalarial), amiodarone, antipsychotics (eg, phenothiazines), barbiturates, benperidol, brigatinib, topical brimonidine, nondihydropyridine Ca channel blockers, diazoxide, dipyridamole, disopyramide, dronedarone, floctafenine, herbs (hypotensive properties), lormetazepam, methoxyflurane, midodrine, molsidomine, naftopidil, nicergoline, nicorandil, nifedipine, obinutuzumab, opioids (eg, anilidopiperidine), pentoxifylline, phosphodiesterase 5 inhibitors, propafenone, prostacyclin analogues, quinagolide, regorafenib, reserpine, rivastigmine, ruxolitinib, terlipressin, tofacitinib. Decreased levels/effects of β₂-agonists, nasal/oral/inhalation/racemic/systemic epinephrine, theophylline derivatives. Decreased levels/effects w/ amphetamines, barbiturates, bosentan, brigatinib, bromperidol, moderate/strong CYP3A4 inducers, dabrafenib, deferasirox, dexmethylphenidate, enzalutamide, erdafitinib, herbs (hypertensive properties), ivosidenib, lorlatinib, methylphenidate, mitotane, NSAIDs, rifamycin derivatives, sarilumab, siltuximab, tocilizumab, yohimbine.

Beta-Blockers

C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.

D